写简历的技巧：基础药物的抗癌co-delivery lipophile
Co-delivering紫杉醇和核阳离子固体脂质纳米粒子与阳离子的固体脂质纳米粒子与核紫杉醇co-delivery制定。乳化凝固的方法被用于基于1.2 -dioleoyl-sn-glycero-3ethylphosphochonline cslN做准备。电动电势是用于描述cSLN装满PTX迟钝的小干扰RNA凝胶复合物(Yu et al .,2011)。PcSLN大小从空cSLN在本质上是不同的。cSLN利用率增强细胞水平的吸收dsRNA癌KB细胞内的荧光。这些细胞存在于人类的上皮细胞。这是进一步结合PcSLN络合dsRNA通过荧光标记。这导致促进最大吸收。
写简历的技巧：基础药物的抗癌co-delivery lipophile
小干扰rna co-delivery治疗,siRNA特定MCL1人类是复杂与PcSLN(Yu et al .,2011)。siRNA特定的控制在这种情况下的肤色在PcSLN荧光素酶。MC1 mRNA的水平减少KB细胞内的一个重要的方式在接受治疗的complexsion siMCL PcSLN。总的来说,这篇文章演示了cSLN潜力开发各种基础药物的抗癌co-delivery lipophile系统以及siRNAs治疗。
写简历的技巧：基础药物的抗癌co-delivery lipophile
Co-delivering paclitaxel and siRNa through cationic solid lipid nano-particles nano-particles with cationic solids of lipids were formulated for paclitaxel co-delivery with siRNA. Methods of emulsification solidification were used for preparing cslN based on 1.2-Dioleoyl-sn-glycero-3ethylphosphochonline. Zeta potential was used for characterizing the cSLN loaded with PTX as well as retardation of gels with small interfering RNA complexes (Yu et al., 2011). The PcSLN sizes were not essentially different from the empty cSLN. The cSLN utilization enhanced the uptake at cellular level of dsRNA fluorescence within the carcinoma KB cells. These cells are present in the epithelium of humans. This is further combined with PcSLN complexing it to dsRNA labelled through fluorescence. This results in promotion of maximum uptake.
写简历的技巧：基础药物的抗癌co-delivery lipophile
For therapeutic siRNA co-delivery, siRNA specific MCL1 for humans was complexed in relation to PcSLN (Yu et al., 2011). The control in this situation was complexion of siRNA specific to luciferase over PcSLN. The levels of MC1 mRNA were reduced in an essential manner within the cells of KB undergoing treatment with complexsion of siMCL over PcSLN. Collectively, the article demonstrated the cSLN potential for developing various lipophile based drugs for anti-cancer co-delivery systems as well as siRNAs therapeutically.
